ENZA-P in The Lancet Oncology

Lu-177 PSMA-617 + enzalutamide vs. enza alone:

● ↑PFS: 13.0 vs 7.8, hazard radio 0.43
● PSA90 response 78% vs 37%
● PSA50 response 93% vs. 68%
● no additional side effects

Incredible work from Louise Emmett Ian Davis & ANZUP team

Serial ctDNA testing from IMVIGOR11 (post cystectomy in muscle invasive bladder cancer) show that ctDNA-ve patients (n=171) with a minimum of 12months follow up have 10% relapse rates and almost no deaths #EAU24 . Do we need to give adjuvant therapy to those as such low risk?

Brilliant work from a brilliant trainee! Nice to see her hard work come to fruition and hopefully we’ll see improvements for this population when EV/pembro becomes available. #bladdercancer ESMO - Eur. Oncology #ESMOAsia23

Our 2023 @ANZUPTrials #GURapidFire concludes! Thanks to our co-convenors, mentors & mentees: Ciara Conduit Andrisha Inderjeeth Ian Davis #AnnaKuchel 💉💉💉A/Prof. Haryana Dhillon💉💉💉 #DickonHayne DrAndrewWeickhardt Chris Oldmeadow @doccharris0 Shankar Siva & our sponsors Astellas Pharma US AstraZeneca Bristol Myers Squibb Merck @MSD

Our 2023 @ANZUPTrials #GURapidFire program is underway. Thanks to Co-Convenors Ciara Conduit &@AndrishaI & our great mentors Ian Davis #AnnaKuchel 💉💉💉A/Prof. Haryana Dhillon💉💉💉 #DickonHayne DrAndrewWeickhardt Chris Oldmeadow Carole Harris and Shankar Siva for this expert, interactive program on #GUCancer

Great to share this work in people with #tscsm .
Well done to Ciara Conduit amanda hutchinson
#SurvOnc #PsyOnc #OzOnc ANZUP POCOG COSA Survivorship USYD Psychology

Congrats to Study Chair Ben Tran & the team for recruiting their 100th patient (by site PI Dr Jeremy Lewin Peter Mac Cancer Centre) on the ANZUP #TesticularCancer translational study #CLIMATE . Now has reached 50% recruitment! WEHI (Walter and Eliza Hall Institute) Ciara Conduit Cancer Australia Ian Davis

⁦Christopher Sweeney, MBBS⁩ giving an excellent discussion on placing PSMAFore data in context. ⁦Thomas Hope⁩ ⁦Alan Tan⁩ ⁦Toni Choueiri, MD⁩ ⁦Michael Morris⁩ #ESMO2023

Eloquent discussion from Andrea Apolo, M.D. National Cancer Institute synthesizing data from #EV302 & #CM901 . Loved the fact that she offered a strong, definitive opinion on the 'winner' in the battle between these options. Also (not shown) great outline of remaining questions - what comes after EVP?

#ESMO23 #YObrunch session 1️⃣ - super insightful talk & educational discussion around #LGBTQIA cancer care by Alison May Berner 👩🏻‍⚕️🏳️‍🌈🧬👩🏻‍🔬; something that’s definitely still lacking in our oncology training to date.

Strongly recommend #YoungOncologists to watch this #ondemand , if you missed this.

So lucky & proud of this work! | Full article: What is ethically required to adapt to intellectual disability in #cancer care? A case study of #testicularcancer management tandfonline.com/doi/full/10.31… | Peter Mac Cancer Centre GU Cast | Urology podcast!

Pleased to share The Lancet Oncology LENVA-PEMBRO across RCC variant histologies: papillary RCC, unclRCC and chromophobe RCC … interim ESMO - Eur. Oncology #ESMO22 and final Chung-Han Lee 李宗翰, MD/PhD ASCO #ASCO23

full text: authors.elsevier.com/a/1hP1c5EIIgLp…
Thanks to all who change
rareRCC pts Tx!

Congratulations Andrisha Inderjeeth on winning the best of the best oral presentation at ANZUP #anzup23 for BLADDA real world evidence! GU Cast | Urology podcast! Gibbs Lab Peter Mac Cancer Centre WEHI (Walter and Eliza Hall Institute)

Fresh from a tour of the penguins, koalas and kangaroos, superstar Andrea Apolo, M.D. delivers a great update on bladder cancer #ANZUP23